64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4

Bioorg Med Chem. 2009 Feb 15;17(4):1486-93. doi: 10.1016/j.bmc.2009.01.014. Epub 2009 Jan 15.


CXCR4 is a chemokine receptor which has been shown to be exploited by various tumors for increased survival, invasion, and homing to target organs. We developed a one step radiosynthesis for labeling the CXCR4-specific antagonist AMD3100 with Cu-64 to produce (64)Cu-AMD3100 with a specific activity of 11.28Ci/ micromol (417GBq/ micromol) at the end of radiosynthesis. Incorporation of Cu(II) ion into AMD3100 did not change its ability to inhibit cellular migration in response to the (only) CXCR4 ligand, SDF-1/CXCL12. (64)Cu-AMD3100 binding affinity to CXCR4 was found to be 62.7 microM. Biodistribution of (64)Cu-AMD3100 showed accumulation in CXCR4-expressing organs and tissues, a renal clearance pathway, and an anomalous specific accumulation in the liver. We conclude that (64)Cu-AMD3100 exhibits promise as a potential PET imaging agent for visualization of CXCR4-positive tumors and metastases and might be used to guide and monitor anti-CXCR4 tumor therapy.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Calcium Signaling / drug effects
  • Cell Line, Tumor
  • Copper Radioisotopes / chemistry*
  • Diagnostic Imaging / methods
  • Heterocyclic Compounds / chemistry*
  • Heterocyclic Compounds / metabolism
  • Heterocyclic Compounds / pharmacology
  • Humans
  • Isotope Labeling / methods
  • Jurkat Cells
  • Mice
  • Mice, Inbred C57BL
  • Positron-Emission Tomography / methods
  • Protein Binding
  • Radiopharmaceuticals / chemical synthesis*
  • Radiopharmaceuticals / metabolism
  • Radiopharmaceuticals / pharmacology
  • Receptors, CXCR4 / analysis*
  • Receptors, CXCR4 / antagonists & inhibitors
  • Signal Transduction / drug effects


  • Copper Radioisotopes
  • Heterocyclic Compounds
  • Radiopharmaceuticals
  • Receptors, CXCR4
  • plerixafor